Focus: Fate Therapeutics is a public biotechnology company focused on stem cell-modulating therapeutics and cell therapy platforms for cancer and immune disorders. The company operates as a clinical-stage developer with a diversified pipeline spanning oncology and autoimmune indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Ideal for early-career researchers and clinical professionals seeking cell therapy expertise in a resource-constrained but intellectually rich environment; unsuitable for those prioritizing financial stability or rapid career advancement via product launches.
Help build intelligence for Fate Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Fate Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside - TradingView
Fate Therapeutics, Inc. Stock 12‑Month Price Target Cut to $6.07, Implies 215% Upside TradingView
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history - Yahoo Finance Singapore
Fate Therapeutics, Inc. (FATE) stock price, news, quote and history Yahoo Finance Singapore
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy - Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercial strategy Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercialization - Investing.com
Fate Therapeutics appoints Jamie Harrell to lead commercialization Investing.com
Fate Therapeutics names Jamie Harrell SVP of commercial operations - StreetInsider
Fate Therapeutics names Jamie Harrell SVP of commercial operations StreetInsider
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Toward clinically actionable lupus biomarkers: a roadmap for research, validation, and translation.
Induced pluripotent stem cell-derived natural killer cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo